Please login to the form below

Not currently logged in

KRAS mutation

This page shows the latest KRAS mutation news and features for those working in and with pharma, biotech and healthcare.

Routine gene test could guide use of cancer chemotherapy, new study shows

Routine gene test could guide use of cancer chemotherapy, new study shows

Separate data from a clinical trial showed that patients with another mutation in the KRAS gene called KRASG13 – 8% of those in the study – saw their median survival triple with the ... treatment. For those without KRAS mutations, survival was found

Latest news

More from news
Approximately 1 fully matching, plus 17 partially matching documents found.

Latest Intelligence

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts


Add my company

We know what it takes to create brands, to start new conversations, to simply communicate complex science, to change lives…...

Latest intelligence

Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
Humancomms for humancare?
Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...